Form 4: Acura Pharmaceuticals Director William Skelly Acquires 50,000 Shares Through Restricted Stock Unit Exchange

Director William Skelly of Acura Pharmaceuticals acquired 50,000 shares of common stock through the exchange of restricted stock units on January 2, 2025.

Summary

• William Skelly, a director at Acura Pharmaceuticals, exchanged 50,000 restricted stock units for 50,000 shares of common stock on January 2, 2025.
• This transaction was part of a previously granted restricted stock unit plan.
• The exchange required Skelly to pay the par value of $0.01 per share.
• Skelly now beneficially owns 625,989 shares of common stock, not including any restricted stock units.
• Additionally, Skelly was granted 50,000 new restricted stock units on January 2, 2025, which will vest quarterly throughout 2025.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed positively as it aligns management interests with shareholders. There are no indications of any negative issues.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.
• The vesting schedule of the new restricted stock units provides an incentive for continued performance.

Future Outlook

The newly granted restricted stock units will vest quarterly throughout 2025, with distributions on vested units expected in January 2026, or earlier upon a change of control.

Industry Context

This transaction is a routine part of executive compensation practices, where stock-based awards are used to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation, including restricted stock units, is a common practice among publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) also use similar equity-based compensation plans for their executives and directors.
• The vesting schedules and terms of these plans are generally aligned with industry norms, aiming to incentivize long-term performance and retention.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it demonstrates management's confidence in the company.
• The vesting schedule of the restricted stock units incentivizes management to focus on long-term value creation.

Next Steps

• The newly granted restricted stock units will continue to vest quarterly throughout 2025.
• Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2026, or earlier upon a change of control.

Key Dates

Keywords

Acura Pharmaceuticals, William Skelly, restricted stock units, common stock, insider trading, share acquisition, director, equity compensation